The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure-Reference-Cited by-同舟云学术

The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure

Published:2017-03-08 Issue:suppl_C Volume:19 Page:C15-C21
ISSN:1520-765X
Container-title:European Heart Journal Supplements
language:en
Short-container-title:

Author:

Nieminen Markku S.¹,Fonseca Cândida²,Brito Dulce³,Wikström Gerhard⁴

Affiliation:

1. Heart and Lung Center, Helsinki University Hospital, Meilahti Tower Hospital, PL 340, 00029 HUS Helsinki, Finland

2. Heart Failure Unit, Department of Internal Medicine, Hospital Sao Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Estrada do Forte do Alto do Duque, 1449-005 Lisboa, Portugal

3. Department of Cardiology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-035 Lisboa, Portugal

4. Department of Cardiology, Institute of Medical Sciences, Uppsala University, Akademiska sjukhuset, Ing.40, 5 tr, 751 85 Uppsala, Sweden

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartjsupp/article-pdf/19/suppl_C/C15/24769395/sux003.pdf

Reference59 articles.

1. Quality of life in chronic disease: a comparison between patients with heart failure and patients with aphasia after stroke;Franzén-Dahlin;J Clin Nurs,2010

2. Mechanisms of chronic muscle wasting and dysfunction after an intensive care unit stay: A pilot study;Dos;Am J Respir Crit Care Med

3. Diaphragm abnormalities in heart failure and aging: mechanisms and integration of cardiovascular and respiratory pathophysiology;Kelley;Heart Fail Rev;

4. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology;Metra;Eur J Heart Fail,2007

5. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC;Ponikowski;Eur J Heart Fail,2016

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antihypertensive Drugs for Pulmonary Hypertension, Cardiovascular Drugs for Right and Left Ventricular Failure;Noninvasive Ventilation. The Essentials;2023

2. Drug Treatment of Heart Failure in Children: Gaps and Opportunities;Pediatric Drugs;2022-01-27

3. Recent and Upcoming Drug Therapies for Pediatric Heart Failure;Frontiers in Pediatrics;2021-11-11

4. The Intensive and Advanced Treatments in the Cardiac Intensive Care Units;Palliative Care in Cardiac Intensive Care Units;2021

5. Levosimendan Efficacy and Safety;Journal of Cardiovascular Pharmacology;2020-06-22